Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery (FARES-2)

Prospective, Multicentre, Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Bleeding Adult Cardiac Surgical Patients

This is a multicentre, active-control randomized, prospective, Phase 3 study in adult cardiac surgery patients. Approximately 500 patients will be randomized at approximately 12 hospitals.

Study Overview

• Status: Recruiting
• Conditions: Bleeding Cardiac Surgery Patients
• Intervention / Treatment: Drug: Octaplex; Drug: Frozen Plasma Product, Human

Detailed Description

Patients will be randomized to receive either 4-factor PCC (Octaplex) or frozen plasma (FP).

The study will compare the hemostatic treatment response to Octaplex versus FP, defined as effective if no additional systemic or surgical hemostatic intervention is required from 60 minutes to 24 hours after initiation of the first treatment dose.

The study will include adult (≥18 years old) patients who undergo cardiac surgery with cardiopulmonary bypass (CPB) and require coagulation factor replacement due to bleeding post-CPB and after adequate reversal of heparin with protamine (as assessed by the surgical staff based on clinical and laboratory criteria) during surgery, and who have a known (e.g., as indicated by INR) or suspected coagulation factor deficiency.

• Study Type: Interventional
• Enrollment (Estimated): 500
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Sigurd Knaub; Phone Number: +41795330529; Email: Sigurd.Knaub@Octapharma.com

Study Locations

• Canada
  • British Columbia
    • New Westminster, British Columbia, Canada, V3L 3W7
      • Recruiting
      • Royal Columbian Hospital
    • Vancouver, British Columbia, Canada, V5Z 1M9
      • Recruiting
      • University of British Columbia and Vancouver Coastal Health Authority
  • Ontario
    • Hamilton, Ontario, Canada, L8L 8E7
      • Recruiting
      • Hamilton Health Sciences Corporation
    • Kingston, Ontario, Canada, K7L 2V7
      • Recruiting
      • Kingston General Hospital
    • London, Ontario, Canada, N6A 5A5
      • Recruiting
      • London Health Sciences
    • Ottawa, Ontario, Canada, K1Y 4W7
      • Recruiting
      • University of Ottawa Heart Institute
    • Toronto, Ontario, Canada, M5B 1W8
      • Recruiting
      • St. Michael's Hospital
    • Toronto, Ontario, Canada, M5G 2C4
      • Recruiting
      • Toronto General Hospital
    • Toronto, Ontario, Canada, M4N 3M5
      • Recruiting
      • Sunnybrook Hospital
  • Quebec
    • Montréal, Quebec, Canada, H1T 1C8
      • Recruiting
      • Montreal Heart Institute
    • Québec, Quebec, Canada, G1V 4G5
      • Recruiting
      • Quebec Laval
• United States
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Recruiting
      • Duke University Health System
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Recruiting
      • University of Oklahoma Health Sciences Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adult (≥18 years old) patients undergoing any index cardiac surgery employing CPB

2. Coagulation factor replacement with PCC or FP ordered in the operating room for:

   1. Management of bleeding, or
   2. Anticipated bleeding in a patient who has been on-pump for >2 hours or has undergone a complex procedure (e.g., aortocoronary bypass [ACB] plus aortic valve replacement)
3. Coagulation factor deficiency, either known to exist (e.g., as indicated by elevated EXTEM clotting time [CT] or INR) or suspected based on the clinical situation
4. Patients who have given written informed consent. In United States patients will provide informed consent prior to surgery. In Canada, informed consent will be obtained after surgery, in accordance with Article 3.7A of the 2018 Tri- Council Policy Statement on the Ethical Conduct for Research Involving Humans.

Exclusion Criteria:

1. Undergoing heart transplantation, insertion or removal of ventricular assist devices (not including intra-aortic balloon pump [IABP]) or repair of thoracoabdominal aneurysm
2. Critical state immediately before surgery with high probability of death within 24 hours of surgery (e.g., acute aortic dissection, cardiac arrest within 24 hours before surgery)
3. Severe right heart failure (clinical diagnosis ± echocardiography)
4. Known contraindications to heparin
5. PCC required for reversal of warfarin or direct oral anticoagulant (DOAC; dabigatran, rivaroxaban, apixaban or edoxaban) within 3 days prior to or during surgery
6. Known thromboembolic event (TEE) within 3 months prior to surgery
7. History of severe allergic reactions to PCC or FP
8. Individuals who have immunoglobulin A (IgA) deficiency with known antibodies against IgA
9. Refusal of allogeneic blood products
10. Known pregnancy
11. Currently enrolled in other interventional clinical trials

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Octaplex; Each participant to receive up to 2 Octaplex infusion intravenously within first 24 hours. Exceeding 24 hours frozen plasma will be administered	Drug: Octaplex; Prothrombin complex concentrate
Active Comparator: Frozen plasma; Each participant will be administered FP according to the local standard	Drug: Frozen Plasma Product, Human; If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients requiring additional hemostatic intervention	Defined as 'effective' if no additional hemostatic intervention, such as administration of any systemic hemostatic agents (including platelets, cryoprecipitate, fibrinogen concentrate, activated recombinant factor VII, other coagulation factor products or a second dose of IMP) or any hemostatic interventions (including surgical re-opening for bleeding) is required from 60 minutes to 24 hours after initiation of the first dose of IMP.	60 minutes to 24 hours after first dose of IMP

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients requiring additional hemostatic intervention based on hemoglobin level	Defined as 'positive' if no additional hemostatic intervention is required and hemoglobin levels decrease by <30% (after accounting for red cell transfusions) from 60 minutes to 24 hours after initiation of the first dose of IMP.	60 minutes to 24 hours after first dose of IMP
Compare the amount of chest tube drainage between the Octaplex and FP groups.		12 and 24 hours after chest closure
Compare the incidence of severe to massive bleeding between the Octaplex and FP groups using a modification of the universal definition of perioperative bleeding (UDPB).		24 hours after surgery start, after the end of CPB and after IMP initiation
Compare efficacy in terms of the mean number of total allogeneic blood components (IMP and non-IMP) transfused between the Octaplex and FP groups.		24 hours after the end of CPB and after IMP initiation
Compare efficacy in terms of the mean number of total non-IMP allogeneic blood components transfused between the Octaplex and FP groups.		24 hours after the end of CPB and after IMP initiation
Compare efficacy in terms of the mean number of total non-IMP allogeneic blood components transfused between the Octaplex and FP groups.		24 hours and 7 days after the end of CPB and after IMP initiation
Compare mean number of individual allogeneic blood components transfused between the Octaplex and FP groups.		24 hours and 7 days after start of surgery, and after the end of CPB and after IMP initiation
Compare efficacy in terms of the incidence of transfusion of individual allogeneic blood components transfused between the Octaplex and FP groups.		24 hours and 7 days after start of surgery and after the end of CPB and after IMP initiation
Compare incidence of administration of non-IMP coagulation factor products between Octaplex and FP groups		24 hours and 7 days after the start of surgery, after the end of CPB and after IMP initiation
Compare incidence of intracerebral hemorrhage between the Octaplex and FP groups		24 hours after start of surgery, after the end of CPB and after IMP initiation
Compare incidence of gastrointestinal hemorrhage between Octaplex and FP groups		24 hours after start of surgery, after the end of CPB and after IMP initiation
Compare incidence of surgical re-exploration between Octaplex and FP groups		24 hours after start of surgery, after the end of CPB and after IMP initiation
Compare the effect of Octaplex versus FP administration on the change in international normalised ratio (INR) before and after therapy administration.	INR reduction will be considered successful if the magnitude of the reduction is >1.0 or the post-treatment level drops below 1.5	Within 30 minutes before to within 60 minutes after the initiation of IMP administration.
Compare the effect of Octaplex versus FP administration on Prothrombin Time (PT)		Within 75 minutes before to within 75 minutes after the initiation of IMP administration
Compare the effect of Octaplex versus FP administration on aPTT		Within 75 minutes before to within 75 minutes after the initiation of IMP administration
Compare the effect of Octaplex versus FP administration on fibrinogen activity		Within 75 minutes before to within 75 minutes after the initiation of IMP administration
Compare the effect of Octaplex versus FP administration on ROTEM EXTEM CT		Within 75 minutes before to within 75 minutes after the initiation of IMP administration
Compare the effect of Octaplex versus FP administration on ROTEM EXTEM MCT		Within 75 minutes before to within 75 minutes after the initiation of IMP administration
Compare the effect of Octaplex versus FP administration on ROTEM FIBTEM MCF		Within 75 minutes before to within 75 minutes after the initiation of IMP administration
Compare the effect of Octaplex versus FP administration on platelets		Within 75 minutes before to within 75 minutes after the initiation of IMP administration
Comparison of incidence of serious treatment-emergent adverse events between Octaplex and FP groups		From start of IMP administration up to 30 days post-operatively
Comparison of the duration of mechanical ventilation between Octaplex and FP groups		From start of IMP administration up to 30 days post-operatively
Comparison of the duration of ICU stay between Octaplex and FP groups		From start of IMP administration up to 30 days post-operatively
Comparison of the duration of hospitalization between Octaplex and FP groups		From start of IMP administration up to 30 days post-operatively
Comparison of the incidence of death between Octaplex and FP groups		From start of IMP administration up to 30 days post-operatively
Comparison of the number of days alive and out of hospital between Octaplex and FP groups		From start of IMP administration up to 30 days post-operatively
Compare total time elapsed from initiation of the first dose of IMP to arrival at the ICU room between the Octaplex and FP groups.		From initiation of IMP to arrival at ICU room (within 24 hours)

Collaborators and Investigators

• Sponsor: Octapharma

Study record dates

Study Major Dates

• Study Start (Actual): November 10, 2022
• Primary Completion (Estimated): August 1, 2024
• Study Completion (Estimated): August 1, 2024

Study Registration Dates

• First Submitted: August 18, 2022
• First Submitted That Met QC Criteria: August 29, 2022
• First Posted (Actual): August 31, 2022

Study Record Updates

• Last Update Posted (Actual): April 11, 2024
• Last Update Submitted That Met QC Criteria: April 10, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Hemorrhage
• Other Study ID Numbers: LEX-211

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No